The Multiple Facets of ABCB4 (MDR3) Deficiency

Area of Science:

• Hepatology
• Genetics
• Biochemistry

Background:

• ABCB4 (MDR3) is a canalicular membrane lipid translocator essential for phosphatidylcholine transport.
• Genetic mutations in ABCB4 are linked to several hepatobiliary disorders.
• These disorders include Progressive Familial Intrahepatic Cholestasis type 3, gallstone diseases, and intrahepatic cholestasis of pregnancy.

Purpose of the Study:

• To review the spectrum of hepatobiliary diseases caused by ABCB4 mutations.
• To discuss current and potential therapeutic strategies for these conditions.
• To highlight the clinical manifestations and management of ABCB4-associated liver diseases.

Main Methods:

• Literature review of studies on ABCB4 mutations and associated hepatobiliary diseases.
• Analysis of clinical presentations, diagnostic features, and treatment outcomes.
• Synthesis of information on therapeutic interventions, including ursodeoxycholic acid (UDCA) and emerging treatments.

Main Results:

• ABCB4 mutations cause PFIC type 3, characterized by cholestasis, cirrhosis, and portal hypertension.
• Patients may develop cholesterol gallstones, intrahepatic microlithiasis, or brown pigment stones.
• Intrahepatic cholestasis of pregnancy in affected women poses risks to both mother and fetus.

Conclusions:

• ABCB4 mutations result in a range of serious hepatobiliary conditions.
• UDCA provides partial benefit for some patients, with liver transplantation often necessary for PFIC type 3.
• Further research into ABCB4 dysfunction may lead to novel therapeutic approaches for these liver diseases.